TIDMGENI

RNS Number : 1468C

GENinCode PLC

08 June 2023

GENinCode Plc

("GENinCode" or the "Company")

Posting of Annual Report to Shareholders and Notice of Annual General Meeting

Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease, confirms that the Annual Report and Accounts for the year ended 31 December 2022 and the Notice of Annual General Meeting ("AGM") have been posted to shareholders.

A copy of the 2022 Annual Report and Accounts, the Notice of AGM and accompanying form of proxy is now available to download from the Company website in accordance with AIM Rule 20:

https://investors.genincode.com/investors

The AGM will be held in person at the offices of Cenkos Securities plc, 6,7,8 Tokenhouse Yard, London EC2R 7AS on Friday, 30 June 2023 at 2.00 p.m.

For more information visit www.genincode.com

Enquiries:

 
 GENinCode Plc                                                           www.genincode.com or via Walbrook PR 
 Matthew Walls, CEO 
 Paul Foulger, CFO 
 Stifel Nicolaus Europe Limited (Nomad and Joint Broker)                             Tel: +44 (0)20 7710 7600 
 Alex Price / Ben Maddison / Richard Short 
 
   Cenkos Securities Plc (Joint Broker)                                              Tel: +44 (0)20 7397 8900 
 Giles Balleny 
 Dale Bellis / Michael Johnson (Sales) 
 
   Walbrook PR Limited                                         Tel: 020 7933 8780 or genincode@walbrookpr.com 
   Anna Dunphy / Louis Ashe-Jepson / Phillip Marriage

About GENinCode:

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.

GENinCode operates business units in the UK, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc.

GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict the onset of cardiovascular disease.

About Cardiovascular Disease (CVD):

CVD is the leading cause of death globally, taking an estimated 17.9 million lives each year. CVD is a group of disorders of the heart and blood vessels and include coronary heart disease, cerebrovascular disease, rheumatic heart disease and other conditions. More than four out of five CVD deaths are due to heart attacks and strokes, and one third of these deaths occur prematurely in people under 70 years of age.

CVD causes a quarter of all deaths in the UK and is the largest cause of premature mortality in deprived areas with the NHS 10 Year Plan identifying CVD as the single biggest area where the NHS can save lives over the next 10 years. CVD is largely preventable, through lifestyle changes and a combination of public health and NHS action on smoking and tobacco addiction, obesity, tackling alcohol misuse and food reformulation.

Early detection and treatment of CVD can help patients live longer, healthier lives. Too many people are still living with undetected, high-risk conditions such as high blood pressure, raised cholesterol, and atrial fibrillation (AF). The NHS 10 Year Plan is working towards people knowing and managing risks around their 'ABC' (AF, Blood pressure and Cholesterol).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NOALVLFBXQLLBBV

(END) Dow Jones Newswires

June 08, 2023 08:31 ET (12:31 GMT)

Genincode (LSE:GENI)
Historical Stock Chart
From Dec 2024 to Jan 2025 Click Here for more Genincode Charts.
Genincode (LSE:GENI)
Historical Stock Chart
From Jan 2024 to Jan 2025 Click Here for more Genincode Charts.